A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients

Eric J. Lawitz, John M. Hill, Thomas Marbury, Michael P. DeMicco, William Delaney, Jenny Yang, Lisa Moorehead, Anita Mathias, Hongmei Mo, John G. McHutchison, Maribel Rodriguez-Torres, Stuart C. Gordon

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Fingerprint

Dive into the research topics of 'A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science